Anticoagulation
Conditions
Keywords
Survey, Effectiveness of risk minimization measures, Rivaroxaban, Anticoagulants
Brief summary
This cross-sectional epidemiologic study measured physician and patient awareness and understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert card.
Interventions
BEHAVIORALRivaroxaban (Xarelto, BAY59-7939)
Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
Sponsors
Janssen Research & Development, LLC
RTI Health Solutions
Bayer
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Inclusion criteria: Physician eligibility: * Prescription of rivaroxaban in the past 6 months for adult patients for the Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (SPAF) or Treatment of deep venous thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT. Patient eligibility: * Use of rivaroxaban for SPAF or DVT within the previous 3 months; aged 18 years and above; able to understand and complete the consent form and patient questionnaire.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Knowledge and understanding of patients regarding the key safety information contained in the patient alert card assessed by paper-based questionnaire | Up to 18 months |
| Knowledge and understanding among physicians regarding key safety information contained in the prescriber guide assessed by web-based questionnaire | Up to 18 months |
Countries
France, Germany, Spain, United Kingdom
Outcome results
None listed